查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835362

颅内支架市场按产品类型、材料、涂层、适应症、最终用户和分销管道划分－2025-2032 年全球预测

Intracranial Stents Market by Product Type, Material, Coating, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年颅内支架市场将成长 28.88 亿美元，复合年增长率为 15.19%。

主要市场统计数据
预测年份（2024年） 9.0351亿美元
基准年（2025年） 1,038,440,000美元
预测年份（2032年） 2,888,000美元
复合年增长率（%） 15.19%

全面介绍颅内支架，涵盖临床需求、设备演变、监管背景以及临床实施的实际考虑

颅内支架是治疗动脉瘤疾病和颅内狭窄的重要工具，处于工程创新与急性神经血管治疗之间的关键交会点。过去二十年，器械设计师和介入神经放射学不断改进支架结构、材料和置入技术，以提高其在迂曲脑血管中的可操作性，并促进长期血管重塑。这一演变反映了临床反馈、诊断成像技术进步和製造能力之间的持续对话，三者均致力于最大限度地降低围手术期风险，同时扩大可治疗病变的范围。

如今，临床医生面临复杂的决策矩阵，需要考虑器械外形、径向力、透视可见度、与辅助器材的兼容性等等。同时，法律规范和付款方的期望也越来越要求提供强有力的临床证据，证明器械具有持久的疗效和良好的安全性。因此，开发重点正从简单的机械支架转向包含标靶给药、新型合金和精密表面处理的整合解决方案。这些趋势正在重塑器械开发流程，并改变每个外科中心的器械应用动态。

因此，理解颅内支架需要多面向的观点，涵盖器材层面的科学、临床工作流程、医院采购惯例以及不断发展的报销模式。对于寻求将产品策略与临床需求相结合的相关人员，迫切需要将营运层面的洞察和监管现状转化为商业性可行的设计，从而在医疗系统采购限制的前提下显着改善患者预后。

设备工程、临床技术和商业性方法的关键变革将重新定义颅内支架的开发和应用

在技​​术突破与临床实践变革的共同推动下，颅内支架领域正在经历变革性变革。材料创新，尤其是镍钛合金和钴铬合金加工製程的进步，使得低剖面支架能够在保持径向强度的同时提高输送能力。同时，雷射切割和编织结构的改进也扩展了支架的选择范围，使其能够更好地贴合病变形态。这些工程学上的进步，加上旨在调节新生内膜增生和降低血管再阻塞风险的药物释放型表面处理的日益普及，标誌着生物活性植入物正被更广泛地应用。

在手术方面，影像导引导航和微导管平台的采用扩大了血管内团队的治疗范围，使他们能够治疗更远端、更复杂的解剖结构。这种能力的转变迫使製造商优化支架的可视性、适配器以及与导流器和栓塞线圈等辅助器具的兼容性。同时，医疗保健系统正在强调基于价值的采购，并要求显着降低併发症发生率、手术时间和下游资源利用率。因此，产品蓝图和商业策略正与可衡量的临床和经济终点更加紧密地结合。

最后，数位化工具和临床医生的直接管道正在重塑培训、上市后监测和产品迭代。远距监考、数位化病例库以及数据驱动的上市后註册系统正在加速营运商和开发商之间的反馈循环，缩短从临床洞察到产品改进的时间。总而言之，这些转变描绘出一个市场走向整合的、循证主导的解决方案的蓝图，这些解决方案将机械改进与生物和数位增强相结合。

2025 年关税变化将如何重塑整个颅内支架生态系统的供应链、采购行为、监管计画和商业策略

2025年关税的征收和贸易政策的调整，为全球供应链带来了巨大的复杂性，并对颅内支架的製造、采购和定价策略产生了显着的下游影响。依赖国际供应网路取得关键原料、精密合金加工和专业契约製造的製造商正面临更高的到岸成本和更长的前置作业时间。这些压力迫使一些相关人员重新评估筹资策略，许多企业正在加速近岸外包、双重采购和替代供应商资格认证的计划，以保持生产连续性并应对投入成本波动。

由于资金配置限制以及对医疗设备定价日益敏感，医院和网路采购团队正面临越来越严格的审查。付款人和医疗系统对成本驱动因素和生命週期经济效益的透明度要求越来越高，而证明併发症发生率、再入院率和总照护成本的降低也变得日益重要。因此，製造商正透过强调基于价值的合约、延长保固期和捆绑定价模式来应对这项挑战，这些模式旨在协调奖励并降低采购风险。

监管和临床研究的时间表也在根据关税主导的不确定性进行调整。参与全球临床临床实验的申办者正在重新评估其供应计画和紧急计画，以确保持续供应临床实验设备。此外，如果关税导致零件成本上升，规模较小的创新企业可能会感受到不成比例的负担，迫使他们做出整合生产、寻求许可或与规模更大的现有企业合作等决策。总而言之，贸易措施的累积效应放大了供应链韧性、商业性灵活性以及贯穿整个产品生命週期的清晰价值主张的重要性。

可操作的细分洞察，将设备架构、材料科学、涂层生物学、适应症、最终用户需求和分销策略整合到一条连贯的商业化路径中

细分市场揭示了临床需求、技术创新和商业策略的交汇点，从而创造出差异化的价值提案。根据产品类型，市场分为球囊扩张型和自扩张式两种结构。在自扩张式产品类别中，编织式和雷射切割式设计在性能上各有优劣，这会影响复杂解剖结构的临床选择。虽然球囊扩张型在精准部署和血管支架至关重要的情况下仍然适用，但自扩张式编织式设计通常在曲折的脑血管中具有卓越的顺应性和血流改向特性。

钴铬合金、镍钛合金和不锈钢各自具有独特的径向强度、弹性和渗透性。镍钛合金因其超弹性和形状记忆性而备受推崇，支援低调输送和抗血管回缩性。钴铬合金在细支柱几何形状中提供高径向力，而不銹钢在某些适应症和製造方法中仍然是经济高效的选择。

涂层策略进一步提升了产品定位。当能够耐受长期金属-宿主相互作用时，裸金属设计颇具吸引力，而药物释放型涂层则正在被探索用于减轻新生内膜增生。在药物释放型方法中，基于紫杉醇和Sirolimus的製剂具有独特的生物机制和释放动力学，从而影响了临床试验设计和应用模式。针对动脉瘤的器械必须同时适应动脉瘤和囊状形态，因此需要灵活性，并且通常需要辅助的血流转移策略。同时，狭窄介入措施需要区分动脉粥状硬化和血栓性病因，以及抗血小板药物和手术通讯协定。

最终用户和分销管道透过塑造获取途径和教育途径完善了细分市场。诊所和医院的诊疗量和资源状况各不相同，诊疗量大的三级医疗中心往往是尖端设备的早期采用者，而社区医院则青睐经济高效、易于部署的设备。依赖直销的分销策略可以透过现场人员和数位化互动提供强化临床培训，并结合电商管道简化补货流程。这些细分的综合层面可以指导产品开发、临床证据产生和商业化策略，使医疗设备属性与营运商需求和采购实际情况一致。

区域资讯解释了临床能力、监管方法和製造生态系统的差异将如何影响美洲、欧洲/中东/非洲和亚太地区的设备采用

区域动态对颅内支架的采用、监管和製造策略有着强大的影响，因此，深入了解地域差异对于有效规划至关重要。美洲地区神经血管中心高度集中，报销框架成熟，这使得先进设备平台能够早期采用，但采购委员会越来越要求提供明确的经济价值证据，以补充临床表现。因此，寻求在美洲地区发展的公司优先考虑严格的临床数据、上市后註册以及与COE网路的直接合作，以加速采用并为产品的迭代改进提供资讯。

欧洲、中东和非洲地区（EMEA）市场格局复杂，监管环境、报销水准和医院能力差异巨大。欧洲的监管趋同和强大的临床研究生态系统鼓励进行多中心研究，而许多市场的医疗保健支付方则注重成本效益和比较有效性研究。虽然手术量和基础设施限制可能会减缓中东和非洲新兴市场的神经介入技术应用，但仍有大量机会，可以改进低成本设备并投资有针对性的培训项目，以提升介入神经放射学能力。

亚太地区既是製造业中心，也是快速发展的需求中心。本地製造能力、熟练介入医师的可用性以及多样化的报销环境，都需要製定平衡全球产品标准与本地客製化的策略。与区域经销商、区域临床领导者和製造外包製造商合作可以加快产品上市速度并优化成本结构，而针对特定区域的临床证据则可以提高付款人的接受度和临床医生的信心。在每个地区，根据当地实际情况调整监管策略、临床证据项目和供应链规划，仍然是成功进入市场和扩大规模的关键。

策略企业洞察重点在于现有企业、创新者和供应商如何利用临床数据、製造伙伴关係和服务模式来获得竞争优势

主要企业的行动揭示了市场领导和挑战者如何将技术能力转化为竞争优势。成熟的医疗设备製造商投入巨资，不断改进合金加工製程、支架几何形状和输送系统，同时透过註册和随机试验累积大量临床证据，以支持其与付款人对话。这些公司通常会投资全球培训网路和内部现场团队，以支援高度复杂的流程，并与主要医疗系统签订长期合约。

较小的创新者和新兴企业往往专注于颠覆性材料、新型涂层化学或专有部署机制，以满足特定未满足的临床需求。规模化发展路径通常包括：建立有针对性的临床证据，与大型製造商建立分销和生产策略合作伙伴关係，或探索收购以加速发展。契约製造製造商和零件供应商透过提供精密加工、先进的精加工和涂层技术，在降低器械商业化所需的资本强度方面发挥关键作用。

在这种竞争格局中，成功的公司将严谨的临床专案与差异化技术平台和强大的供应链策略相结合。丰富的智慧财产权组合、在多个司法管辖区的监管审批，以及透过註册和绩效指标证明其在现实世界中的效用，是市场领导脱颖而出的关键因素。此外，整合数位化培训、远端监考和数据主导的上市后监测的公司，更有能力缩短产品采用週期，并在不同产品世代之间保持临床医生的参与度。

为领导者提供可行的建议，以同步产品蓝图、供应链弹性、临床证据和混合商业策略，从而加速采用

产业领导者应推行协作议程，协调产品开发、临床策略和商业性执行，从而抓住新兴机会，同时降低系统性风险。首先，优先考虑模组化产品蓝图，以便支架结构和涂层能够不断迭代改进，这将降低开发风险，并透过渐进式性能改进加速临床医生的采用，而无需彻底重新设计平台。同时，投资于可量化安全性和下游资源利用率的受控临床试验和高品质註册库，将为付款人和医疗系统提供更强大的价值提案。

第二，透过实现关键合金和製造工艺供应商多元化、确定二级生产地点以及协商库存和前置作业时间协议来增强供应链韧性，从而应对关税相关的中断。考虑策略性近岸外包，并与区域製造外包合作，以降低国际贸易波动带来的风险，并缩短关键市场的补货週期。第三，采用混合市场进入模式，将大批量生产基地的直销和数位化互动与地理覆盖范围的经销商伙伴关係关係相结合，并利用电子商务解决方案进行补货和备件维修。

最后，将商业化与强大的临床医生支援计划相结合，包括实践培训、远端指导以及追踪实际表现的成果仪表板。将这些倡议与灵活的商业条款相结合，例如与结果挂钩的合约以及与客户共用手术和术后风险的捆绑产品。透过整合这些营运、临床和商业性行动，领导者可以强化其市场定位，并加速其在不同医疗环境中的永续应用。

一种透明的多方法调查方法，结合临床证据审查、相关人员访谈、供应链尽职调查和情境分析，以产生可操作的情报

本调查方法整合了多种证据流，确保假设和限制的透明性，同时得出严谨且可重复的结论。研究首先全面回顾同侪审查文献、临床试验註册和监管备案文件，以建构关于器械安全性、有效性和操作规范的基础依证。除了此案调查方法外，还开展了针对性访谈，访谈对象包括临床医生、采购主管和品管官员，旨在了解现场对器械性能、培训需求和采购标准的观点。

透过与零件供应商、契约製造和材料专家的磋商，进行了供应链映射和技术实质审查调查，以确定製造限制和应对关税中断的可行缓解措施。该研究还纳入了临床登记和真实世界数据集的分析，以支持试验结果并观察纵向结局。透过交叉检验访谈见解、已发表的研究和监管文件进行资料三角检验，以确保结论反映的是趋同证据，而非孤立的轶事。

在整个过程中，我们运用情境分析来检验策略方案在各种交易、报销和临床应用假设下的韧性。方案的局限性，尤其是在出现新证据或存在地域差异的情况下，均被清晰地记录下来，并根据信心度和需要进一步进行初步研究的领域调整了建议。这种定性和定量方法的结合，不仅能得出切实可行的结论，还能阐明每个见解的强度和来源。

简明结论综合了技术进步、临床要求和商业性行为，这些将决定颅内支架领域的成功

颅内支架领域的特点是技术创新日新月异、临床实践日新月异，以及受贸易政策和付款方期望影响的日益复杂的商业性格局。材料、支架几何形状和涂层生物学的进步正在扩展介入神经放射学可用的临床套件，而成像和微导管平台的改进则拓宽了血管内治疗的解剖范围。这些技术进步，加上对比较结果和成本透明度日益增长的需求，正在重新定义商业性成功的标准。

因此，有效的策略应将严谨的临床证据产生、灵活的生产和分销计划以及与购买者优先顺序相符的商业模式相结合。投资于持久临床数据、灵活供应链和以临床医生为中心的培训计画的相关人员将最有能力将技术优势转化为广泛的应用。随着环境的不断发展，持续监测监管变化、报销变化和供应链讯号对于保持策略敏捷性并及时抓住产品差异化和市场成长的机会仍然至关重要。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 生物可吸收支架材料的进展可减少支架内血管再阻塞
  • 动脉瘤治疗中越来越多地采用流量转向器和管道栓塞装置
  • 人工智慧引导部署系统在支架置入中的整合
  • 远距医疗环境中微创神经介入技术的发展
  • 扩展混合手术室，将影像学和颅内手术结合起来
  • 开发具有抗血栓和抗发炎特性的下一代涂层支架
  • 加强医疗设备製造商与神经外科中心之间的策略合作
  • 新兴市场新型颅内支架系统监理核准激增
  • 专注于使用患者特定的 3D 列印神经血管模型进行个人化支架设计
  • 公共医疗保健倡议对经济高效的颅内支架的需求不断增长

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第八章颅内支架市场（依产品类型）

  • 球囊扩张型
  • 自膨胀
    • 编织
    • 雷射切割

9. 颅内支架市场（依材料）

  • 钴铬合金
  • 镍钛合金
  • 不銹钢

10. 颅内支架市场（依涂层）

  • 裸机
  • 药物释放型
    • 紫杉醇
    • Sirolimus

第 11 章颅内支架市场（按适应症）

  • 动脉瘤
    • 纺锤形
    • 囊状
  • 收缩
    • 动脉硬化
    • 血栓性

第 12 章。颅内支架市场（依最终用户）

  • 诊所
  • 医院

13. 颅内支架市场（依通路）

  • 直销
    • 电子商务
    • 现场销售代表
  • 批发商
    • 全国经销商
    • 区域经销商

14. 颅内支架市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第15章颅内支架市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章颅内支架市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Medtronic plc
    • Stryker Corporation
    • Cerenovus LLC
    • MicroPort Scientific Corporation
    • Terumo Corporation
    • Balt Extrusion SAS
    • Acandis GmbH
    • Phenox GmbH
    • Boston Scientific Corporation
    • InspireMD Ltd.
Product Code: MRR-43127F7279D7

The Intracranial Stents Market is projected to grow by USD 2,800.88 million at a CAGR of 15.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 903.51 million
Estimated Year [2025] USD 1,038.44 million
Forecast Year [2032] USD 2,800.88 million
CAGR (%) 15.19%

A comprehensive introduction to intracranial stents that frames clinical needs, device evolution, regulatory context, and practical considerations for clinical adoption

Intracranial stents occupy a critical intersection between engineering innovation and acute neurovascular care, serving as essential tools in the treatment of both aneurysmal disease and intracranial stenosis. Over the past two decades, device designers and neurointerventionalists have refined stent architecture, materials, and deployment techniques to improve navigability through tortuous cerebral vasculature and to enhance long-term vessel remodeling. This evolution reflects a continuous dialogue between clinical feedback, imaging advances, and manufacturing capabilities, with each iteration seeking to minimize periprocedural risk while expanding the spectrum of treatable lesions.

Clinicians now face a complex decision matrix that weighs device profile, radial force, visibility under fluoroscopy, and compatibility with adjunctive devices. Concurrently, regulatory frameworks and payer expectations increasingly demand robust clinical evidence demonstrating durable outcomes and favorable safety profiles. As a result, development priorities have migrated beyond simple mechanical scaffolding toward integrated solutions that incorporate targeted drug delivery, novel alloys, and refined surface treatments. These trends are reshaping device development pipelines and altering adoption dynamics across procedural centers.

Understanding intracranial stents therefore requires a multi-faceted perspective that incorporates device-level science, clinical workflows, hospital procurement practices, and evolving reimbursement paradigms. For stakeholders seeking to align product strategy with clinical need, the imperative is to translate procedural insights and regulatory realities into commercially viable designs that demonstrably improve patient outcomes while fitting within health system procurement constraints.

Key transformative shifts in device engineering, clinical technique, and commercial approaches that are redefining intracranial stent development and adoption

The landscape for intracranial stents is undergoing transformative shifts driven by converging technological breakthroughs and changes in clinical practice. Material innovations, particularly advances in nickel-titanium alloys and cobalt-chromium processing, have enabled lower-profile devices that maintain radial strength while improving deliverability; simultaneously, refinements in laser-cut and braided architectures have expanded device selection to better match lesion morphology. These engineering advances are paralleled by the increasing incorporation of drug-eluting surface treatments designed to modulate neointimal proliferation and reduce restenosis risk, indicating a broader shift toward biologically active implantables.

Procedurally, the adoption of image-guided navigation and enhanced microcatheter platforms has expanded the reach of endovascular teams, enabling treatment of more distal and complex anatomies. This shift in capability has pressured manufacturers to optimize stent visibility, conformability, and compatibility with adjunct devices such as flow diverters and embolic coils. At the same time, healthcare systems are emphasizing value-based procurement, requiring demonstrable reductions in complication rates, procedure times, and downstream resource utilization. Consequently, product roadmaps and commercial strategies are aligning more tightly with measurable clinical and economic endpoints.

Finally, digital tools and direct-to-clinician channels are reshaping how training, post-market surveillance, and product iterations occur. Remote proctoring, digital libraries of procedural cases, and data-driven post-market registries are accelerating feedback loops between operators and developers, which in turn compresses the timeline from clinical insight to product refinement. Taken together, these shifts depict a market moving toward integrated, evidence-driven solutions that combine mechanical sophistication with biological and digital enhancements.

How 2025 tariff changes are reshaping supply chains, procurement behavior, regulatory planning, and commercial strategies across the intracranial stent ecosystem

The imposition of tariffs and trade policy adjustments in 2025 has introduced material complexities across global supply chains, with measurable downstream impacts on intracranial stent manufacturing, procurement, and pricing strategies. Manufacturers that rely on international supply networks for critical raw materials, precision alloy processing, or specialized contract manufacturing face higher landed costs and extended lead times. These pressures have compelled some stakeholders to reevaluate sourcing strategies, with many accelerating plans for nearshoring, dual-sourcing, and qualification of alternative suppliers to preserve production continuity and to manage input-cost volatility.

Procurement teams within hospitals and networks are experiencing heightened scrutiny as device price sensitivity grows alongside constrained capital allocations. Payers and health systems are increasingly requesting transparency on cost drivers and lifecycle economics, heightening the importance of demonstrating reductions in complication rates, readmissions, and total cost of care. As a result, manufacturers are responding by emphasizing value-based contracting, longer-term warranties, and bundled pricing models that align incentives and mitigate procurement risk.

Regulatory and clinical research timelines have also adapted in response to tariff-driven uncertainties. Sponsors engaged in international trials are reassessing supply plans and contingency provisions to ensure continuity of investigational device availability. Moreover, smaller innovators may feel disproportionate strain when tariffs increase component costs, prompting decisions to consolidate manufacturing, pursue licensing, or partner with larger incumbent firms. In sum, the cumulative effect of trade measures is to amplify the importance of supply chain resilience, commercial flexibility, and clear value articulation across the product lifecycle.

Actionable segmentation insights that align device architectures, material science, coating biology, indications, end-user needs, and distribution strategies into coherent commercialization pathways

Segmentation reveals where clinical needs, engineering innovations, and commercial strategies intersect to create differentiated value propositions. Based on product type, the market differentiates between balloon-expandable devices and self-expanding architectures; within the self-expanding category, braided and laser-cut designs present distinct performance trade-offs that influence clinical choice for complex anatomies. Balloon-expandable constructs remain relevant where precise deployment and vessel scaffolding are paramount, while self-expanding braided designs frequently offer superior conformability and flow-modifying characteristics in tortuous cerebral vessels.

Material selection is another primary axis of differentiation, with cobalt-chromium, nickel-titanium, and stainless steel each offering unique profiles in terms of radial strength, elasticity, and radiopacity. Nickel-titanium alloys are prized for superelasticity and shape memory, which support low-profile delivery and resilience against vessel recoil; cobalt-chromium provides high radial force in thin strut geometries; and stainless steel continues to serve as a cost-effective option for specific indications and manufacturing approaches.

Coating strategies further stratify product positioning. Bare metal designs appeal where long-term metal-host interactions are acceptable, whereas drug-eluting coatings are being explored to mitigate neointimal proliferation. Within drug-eluting approaches, paclitaxel and sirolimus-based formulations offer different biological mechanisms and release kinetics, shaping clinical trial designs and adoption patterns. Indication-based segmentation differentiates aneurysm treatment from stenosis management; aneurysm-focused devices must address both fusiform and saccular morphologies, requiring flexibility and, often, adjunctive flow diversion strategies, while stenosis interventions distinguish between atherosclerotic and thrombotic etiologies that drive distinct antiplatelet and procedural protocols.

End user and distribution channels round out the segmentation picture by shaping access and education pathways. Clinics and hospitals represent different procedural volumes and resource profiles, with high-volume tertiary centers often adopting cutting-edge devices earlier, and community hospitals favoring cost-effective, easy-to-deploy options. Distribution strategies that rely on direct sales can provide intensive clinical training through field force or digital engagement and can pair e-commerce channels for streamlined replenishment, whereas distributor networks-both national and regional-offer broader geographic reach and inventory management capabilities. Taken together, these segmentation layers guide product development, clinical evidence generation, and commercialization tactics that align device attributes with operator needs and procurement realities.

Regional intelligence describing how differences in clinical capacity, regulatory approach, and manufacturing ecosystems shape device adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a powerful influence on the adoption, regulation, and manufacturing strategies for intracranial stents, and a nuanced appreciation of geographic differences is essential for effective planning. In the Americas, high concentrations of specialized neurovascular centers and mature reimbursement frameworks support early adoption of sophisticated device platforms, but procurement committees increasingly demand clear evidence of economic value that complements clinical performance. Consequently, companies aiming to grow in the Americas prioritize rigorous clinical data, post-market registries, and direct engagement with center-of-excellence networks to accelerate uptake and inform iterative product improvements.

The Europe, Middle East & Africa region presents a heterogeneous landscape in which regulatory pathways, reimbursement levels, and hospital capabilities vary widely. European regulatory convergence and strong clinical research ecosystems facilitate multi-center studies, while healthcare payors in many markets emphasize cost-effectiveness and comparative effectiveness research. In emerging markets across the Middle East and Africa, constrained procedural volumes and infrastructure limitations can slow adoption, yet there are significant opportunities to tailor lower-cost device variants and to invest in targeted training programs that expand capacity for neurointerventional procedures.

Asia-Pacific represents both a manufacturing hub and a rapidly evolving demand center, with several countries demonstrating accelerated adoption driven by growing neurosurgical capacity and expanding health system investment. Local manufacturing capabilities, availability of skilled interventionalists, and diverse reimbursement environments require strategies that balance global product standards with regional customization. Partnerships with regional distributors, local clinical leaders, and contract manufacturers can shorten time-to-market and optimize cost structures, while region-specific clinical evidence can bolster payer acceptance and clinician confidence. Across all regions, aligning regulatory strategy, clinical evidence programs, and supply chain planning to local realities remains a cornerstone of successful market entry and scaling.

Strategic company insights highlighting how incumbents, innovators, and suppliers are leveraging clinical data, manufacturing partnerships, and service models to secure competitive advantage

Key company behaviors reveal how market leaders and challengers are translating technical capabilities into competitive advantage. Established device manufacturers concentrate investments on iterative improvements to alloy processing, stent geometry, and delivery systems, while cultivating extensive clinical evidence through registries and randomized trials to underpin payer conversations. These firms often invest in global training networks and in-house field force capabilities to support high-complexity procedures and to secure long-term contracts with major health systems.

Smaller innovators and start-ups tend to specialize in disruptive materials, novel coating chemistries, or unique deployment mechanisms that address specific unmet clinical needs. Their pathways to scale typically involve building targeted clinical evidence, pursuing strategic partnerships with larger manufacturers for distribution and production, or seeking acquisition as an acceleration route. Contract manufacturers and component suppliers play a critical enabling role by offering precision machining, advanced finishing, and coating capabilities, thereby lowering the capital intensity required for device commercialization.

Across the competitive landscape, successful companies combine rigorous clinical programs with differentiated technical platforms and resilient supply chain strategies. Intellectual property portfolios, regulatory clearances in multiple jurisdictions, and the ability to demonstrate real-world clinical utility through registries and performance metrics are decisive factors that separate market leaders from the rest. Moreover, firms that integrate digital training, remote proctoring, and data-driven post-market surveillance are better positioned to shorten adoption cycles and to maintain clinician engagement over successive product generations.

Actionable recommendations for leaders to synchronize product roadmaps, supply chain resilience, clinical evidence, and hybrid commercial strategies to accelerate adoption

Industry leaders should pursue a coordinated agenda that aligns product development, clinical strategy, and commercial execution to capture emerging opportunities while mitigating systemic risks. First, prioritize modular product roadmaps that allow iterative improvements to stent architecture and coatings without requiring full platform redesigns; this reduces development risk and accelerates clinician adoption through incremental performance gains. Concurrently, invest in comparative clinical studies and high-quality registries that quantify both safety and downstream resource utilization, enabling stronger value propositions for payers and health systems.

Second, build supply chain resilience by diversifying suppliers for critical alloys and manufacturing steps, qualifying secondary production sites, and negotiating inventory and lead-time agreements that accommodate tariff-related disruptions. Consider strategic nearshoring or partnerships with regional contract manufacturers to reduce exposure to international trade volatility and to shorten replenishment cycles for key markets. Third, adopt hybrid go-to-market models that blend direct sales and digital engagement for high-volume centers with distributor partnerships that ensure geographic reach, leveraging e-commerce solutions for replenishment and service parts.

Finally, align commercialization with a robust clinician support program that includes hands-on training, remote mentoring, and outcomes dashboards to track real-world performance. Pair these initiatives with flexible commercial terms such as outcome-linked contracts or bundled offerings that share procedural and post-procedural risk with customers. By integrating these operational, clinical, and commercial actions, leaders can strengthen market positioning and accelerate sustainable adoption across diverse healthcare environments.

A transparent, multi-method research methodology integrating clinical evidence review, stakeholder interviews, supply chain diligence, and scenario analysis to produce actionable intelligence

The research approach synthesizes multiple evidence streams to produce rigorous, reproducible conclusions while ensuring transparency in assumptions and limitations. The methodology begins with a comprehensive review of peer-reviewed literature, clinical trial registries, and regulatory filings to assemble a foundational evidence base regarding device safety, efficacy, and procedural practices. This desk-based phase is complemented by targeted interviews with clinicians, procurement leaders, and quality officers to capture frontline perspectives on device performance, training needs, and purchasing criteria.

Supply chain mapping and technical due diligence were conducted through consultations with component suppliers, contract manufacturers, and materials experts to verify manufacturing constraints and to identify feasible mitigation strategies for tariff disruptions. The research also incorporated analyses of clinical registries and real-world datasets where available to corroborate trial findings and to observe longitudinal outcomes. Data triangulation occurred through cross-validation of interview insights, published studies, and regulatory documents to ensure that conclusions reflect convergent evidence rather than isolated anecdotes.

Throughout the process, scenario analysis was used to test the resilience of strategic options under different trade, reimbursement, and clinical-adoption assumptions. Limitations were explicitly documented, particularly where evidence was emerging or geographically variable, and recommendations were calibrated to reflect areas of high confidence versus those requiring additional primary research. This blended qualitative and quantitative approach produces actionable intelligence while preserving clarity about the strength and provenance of each insight.

A concise conclusion synthesizing the technical advances, clinical imperatives, and commercial actions that will determine success in the intracranial stent arena

The intracranial stent landscape is characterized by rapid technical innovation, shifting clinical practices, and an increasingly complex commercial context shaped by trade policy and payer expectations. Advances in materials, stent geometry, and coating biology are expanding the clinical toolkit available to neurointerventionalists, while improvements in imaging and microcatheter platforms are broadening the anatomical reach of endovascular therapy. These technical advances, coupled with heightened requirements for comparative outcomes and cost transparency, are redefining commercial success criteria.

Effective strategies will therefore blend rigorous clinical evidence generation with resilient manufacturing and distribution plans, and with commercial models aligned to purchaser priorities. Stakeholders that invest in durable clinical data, flexible supply chains, and clinician-centric training programs will be best positioned to convert technical advantages into widespread adoption. As the environment continues to evolve, ongoing monitoring of regulatory shifts, reimbursement changes, and supply chain signals will remain essential to maintain strategic agility and to seize timely opportunities for product differentiation and market growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancement in bioresorbable stent materials for reduced in-stent restenosis
  • 5.2. Rising adoption of flow diverters and pipeline embolization devices for aneurysm treatment
  • 5.3. Integration of artificial intelligence-guided deployment systems in stent placement
  • 5.4. Growth of minimally invasive neurointerventional techniques in remote healthcare settings
  • 5.5. Expansion of hybrid operating suites for combined imaging and surgical intracranial procedures
  • 5.6. Development of next-generation coated stents with dual antithrombotic and anti-inflammatory properties
  • 5.7. Increasing strategic collaborations between device manufacturers and neurosurgical centers
  • 5.8. Surge in regulatory approvals of novel intracranial stent systems in emerging markets
  • 5.9. Focus on personalized stent designs using patient-specific 3D printed neurovascular models
  • 5.10. Rising demand for cost-effective intracranial stents in public healthcare initiatives

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intracranial Stents Market, by Product Type

  • 8.1. Balloon Expandable
  • 8.2. Self Expanding
    • 8.2.1. Braided
    • 8.2.2. Laser Cut

9. Intracranial Stents Market, by Material

  • 9.1. Cobalt Chromium
  • 9.2. Nickel Titanium
  • 9.3. Stainless Steel

10. Intracranial Stents Market, by Coating

  • 10.1. Bare Metal
  • 10.2. Drug Eluting
    • 10.2.1. Paclitaxel
    • 10.2.2. Sirolimus

11. Intracranial Stents Market, by Indication

  • 11.1. Aneurysm
    • 11.1.1. Fusiform
    • 11.1.2. Saccular
  • 11.2. Stenosis
    • 11.2.1. Atherosclerotic
    • 11.2.2. Thrombotic

12. Intracranial Stents Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals

13. Intracranial Stents Market, by Distribution Channel

  • 13.1. Direct Sales
    • 13.1.1. E Commerce
    • 13.1.2. Field Force
  • 13.2. Distributor
    • 13.2.1. National Distributors
    • 13.2.2. Regional Distributors

14. Intracranial Stents Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Intracranial Stents Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Intracranial Stents Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Medtronic plc
    • 17.3.2. Stryker Corporation
    • 17.3.3. Cerenovus LLC
    • 17.3.4. MicroPort Scientific Corporation
    • 17.3.5. Terumo Corporation
    • 17.3.6. Balt Extrusion S.A.S.
    • 17.3.7. Acandis GmbH
    • 17.3.8. Phenox GmbH
    • 17.3.9. Boston Scientific Corporation
    • 17.3.10. InspireMD Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRACRANIAL STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. INTRACRANIAL STENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. INTRACRANIAL STENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRACRANIAL STENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRACRANIAL STENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRACRANIAL STENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BRAIDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY LASER CUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NICKEL TITANIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY BARE METAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FUSIFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY SACCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY ATHEROSCLEROTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY FIELD FORCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INTRACRANIAL STENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTOR, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY SELF EXPANDING, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DRUG ELUTING, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST INTRACRANIAL STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025